Benign Tumors of the Female Reproductive Tract

Reproductive Age Group - Uterine Masses

 

GnRH agonists

40% to 60% decrease in uterine volume

Hypoestrogenism: reversible bone loss and symptoms: hot  ashes.

limited to short-term use

Regrowth of leiomyomas within a few months after stopping therapy in

about 1/2 women treated

The use of GnRH agonists results in a 40% to 60% decrease in uterine

volume  and  can  be  of  value  in  some  clinical  situations.  Treatment

results in hypoestrogenism, which has been associated with reversible

bone loss and symptoms such as hot  ashes. Thus, treatment has been

Download presentation

Cancel   Download



We think you have liked this presentation. If you wish to

download it, please recommend it to your friends in any social

system. Share buttons are a little bit lower. Thank you!

Buttons:

33

To make this website work, we log user data and share it with processors. To use this website, you must agree to our Privacy Policy, including cookie

policy.  I agree.     

---

limited  to  short-term  use,  although  low-dose  hormonal  replacement

may be e ective in minimizing the hypoestrogenic e ects. Regrowth of

leiomyomas is experienced within a few months after stopping therapy

in  about  one-half  of  women  treated.  Some  indications  for  the  use  of

GnRH agonists in women with leiomyomas are as follows:

1.Preservation  of  fertility  in  women  with  large  leiomyomas  before

attempting conception, or preoperative treatment before myomectomy

2.Treatment of anemia to allow recovery of normal hemoglobin levels

before  surgical  management,  minimizing  the  need  for  transfusion  or

allowing autologous blood donation

3.Treatment  of  women  approaching  menopause  in  an  e ort  to  avoid

surgery

4.Preoperative  
hysterectomy,  

6.Treatment  of  women  with  personal  or  medical  indications  for

delaying surgery.

42